Company Registered Number: 02685083 Charity Registered Number {England & Wales). 1009671 NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) UNAUDITED TRUSTEES. REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 'ACC08L2G* I3223 CCthIPANIES HOUSE
NATIONAL ECZEMA SOCIETY IA Company Umit8d by Guarantee) CONTENTS Page R•ference and Admini$trallve Details of Ihe Charity. its Trustoes and Advisers Trustees. Report 2-10 Stat•m¢nt ol Trnstees. Responsibilitiey 11 Independènt Examinerfs Report 12-13 Consolidated Statement of Finan¢lal A¢ti¥ities 14 Consolidatsd Balance Sheet 15-16 Charity Balance Sheet 17-18 Consolidated Statomont of Cash Flows Not8S to Ihe Financlal Ststsments 20-45
NATIONAL ECZEMA SOCIETY {A Company Llmlted by Guarantee) REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY. ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEhlBER 2022 Trustees E(tsMd Dawes KC. Chair {reswJned 19 May 20221 Ellen Vincent. Vice Chair (resigned 14 September 20221 Stephen Pugh, Treasu1 (appointed to ChaÉr 19 May 2022, resigned as Treasurer 19 May20221 Catherine Escott {resigned 14 September 2022} Johnston {re$igned 14 September 20221 Hannah Kunzjth lappointed 16 March 2022) Dr Simon Lovegrove (appointed 16 March 2022. resigned 14 September 2022) Professor Celia Moss OBE Bhar81 Pandya (apwinbl 16 March 2022) James Pitayanukul (appointed to Treasurer 19 May 20221 Hed Vollers (appnted 16 March 2022} Suzarfft Watson Company registered number 02685083 CharSty registered number lo71 Registered offic• 11 Murray Slreet London NW19RE Chief exe¢utiYe t)ffir & ArKlrew Pffrttor Company se¢retsry Independent Examin•r MHA Chartered ACCJntants Slalulory Audrtor 6th Flt>)r 2 London Wall Place London EC2Y SAU Principal Bankers CAF Bank Ltd National Westmrnster Bank Bardays Bank pk Status and Governlng Document National Eczema Sccth is a charilable company, Iwniled by guarantee. It was incorporated on 6 February 1992 and registered as a charity on 10 March 1992. 11 is govemed by rts ArteS ofAssocia1n. Subsldlary C¢)mpanles Eczema Tradirrfj L"rmrted P•J8 1
NATIONAL ECZEMA SOCIETY IA Company Limited by Guarantee) TRUSTEES. REPORT FOR THE YEAR ENDED 31 DECEMBER 2022 The tru$lefts presenl their annual report together with the financial ststemenls of the Group and the Charty for the year 1 January 2022 to 31 December 2022. The trustees confim) Ihal the Annual Report and financial stalernents of the company compty with the current ststuiory iequiremenls, the requirernenls of the company's governing document and the proviSS of the Staternenl of Recommended Practice ISORP), applicable to charrties preparing their accounts in accordance with the Financial Reporting Standard appluble in the UK and RePUb"C of Ireland IFRS 102). Since the Charity and the Group qualifie$ as small under sedion 383. the Strateg report reqUId of medium and 101ge companies under The Companies Ad 20l IStrateg Report and Direclorfs Report) RegulalKJns 2013 is not required. Purpose and aims Nats'onal Eczema Society was established in 1975 to support people with eczema and their families and lo work on their behalf. We remain deduted to these founding prinCipS and t¢)Jay we continue to help J>eople across the UK by provK4ing evidenc&ba5ed infomiation and adviee about e¢zema and rt5 managernent. We deliverthis in various ways through ourwebsrte, webinars. inslruclional Ve0$, social media CommunatsOns, putrAicalxJns and nurse4upported Helpline. We abo proVe a colleclNe voice for people with eczema. to infom) research and inffluence health poly to wnprove euema Care, and raise 9018r awareness and Urer$AdYQ ofthe ¢ondition peIe affected by e¢zema and the wider public. The prevalence ofe¢zema has irweased over recent decades. and around one in fve Children and one in len aduEts are now impacted by this lrfe-challenging condrtion in the UK. IhThile the reasons for the increase are not fully understc(#J. it d¢es mean the charity's work Is needed more than ever. There is as yet no ¢ure for e¢zema and. unless you have the ¢ondrti)n. it carh be hard to imagine the daily challenge of living wlh relentle55 itching and inflamed. painful skrn. Many healthcare professionals have limited defmatolc4Jy training and timety access lo specialist dermatology heatthcare for people with eczema can often be drficuir. National Eczema Society aims to provide the inlormalftjn and support needed for people to self-manage their e¢zema effe¢tivety, to become experts in their own care. leam from Ihe experiences of others. and proVe the $Surance of knrrfJ they are nol on Iheir own. Ensuring our work delivers t>ur charitable aims We review our activities each year and monitof the impact of our work to ensure we continue to fulfil our purpose of supporting people aff&ted by e¢zema. Among other ways, we assess the Society's performance and achvevemen15 through the number of people we have help&J wth infom)alion and adwce, and the qualrty and consistency of the )UrceS we provide. We consider how planned activ.eS conlribute to the aims and Oblte5 we have se( and in doing this we have referred to the Charty Commission's general guidance on public benefit. We have had regard lo the legrslatwe and regulatory reqUirenIS for disck)siThJ how our charitable objectives have provided such benefrt. and complied with the duty set out in section 4 of the Charities Act 2011. 2022 Adlvlty and a¢hlwements- delivering public benefrt All our chaiilable aclNilies f<xvs on suppcwting people affected by eema and championing their needs, and further our charrtable purposes for the public benefit. Here we present a summary of the Sxiety's work over the year. Page 2
NATIONAL ECZEMA SOCIETY IA Company Limited by Guarantee) TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022 Delivering information and advic• for people living with eczerna The Swiety ¢(tInueS to Pffjde a we range of hb3h quafty. evNJenc&ba5ed informalh?n and advice about eczema and its management for people Ibviry With the condition and their families. Our eczema Helpline provides personalised independent advL¢e and reassurance needed by people struggling lo pe wrth eczema wherever they Ibve in the UK. We receive around 1.500 telephone, ema and message enquiries a year from Pants of children with eczema and adults liTrthng with the condth'on. These ¢overa wide range ofquestions about eczema syrnplcffi5 arHI treatrnents, from the latest biolog drugs lo eczema-friendly clothing. We offer a demialology nurse calkback semce for people who have more complex enquiries. and around 40QA of Callers are helped by one of our experienced dermatol¢)yy nurse advisers. Our Helpline 15 available free of charge to anyone affected by zerna in the UK who needs our support. Alongside our Heline, the produces a WKle range of patient infomalion book15 and factsheels about eczema management and treatment. availab online and in print. We distribute printed copies al events the charty organises and attends, and we provkled over 14,000 copies of our printed publications lo heafihcare professionals during the year. for ¢)nward distribLttion to patients in hospital demiatology Clinics and other healthcare settings. National Eczema Society faclsheets and booklets are updated regulady on a rdling review cycle and checked by healthcare prolessionals to ensure the information is accurate and utolate. We updated and reprinted a number of publrcations over the year. induding our Contact Dermatitis bklet and Gu*Je for Teenagers Living wtth Eczema. We continue to raise awane$S of local vdunteer4ed patient support groups, by providing infom)alK)n and a presence for these gTOUPS on the Society's websrte. Wrth the lifting of Covid restrictions. the Wesl Surrey and NOrthaSt Harnpshire Support Group was able lo retum to k)cal fundraising and swareness-raising. Dr George Moncrieff gave an excellent Ihoughl-provoking talk on the causes of eczema and latest thinking on eczema care at the GroLrp'$ eczema Trnformation day in Guildford in March. It shtraed much is sb"Il not known about eczema, but also h¢)w much pfogiess has been made in management and tTealment appro¥hes over recent years. GTOUP member Vicky Robinson received the Mayorfs Award fof Servrce to the Communty in June. whh recognises positNe community working within the brKough of Guildf¢xd. The award was ri¢hty Oeserved and reflects Vicky's fantastic wort( for the Society over many years, and that of the Wesl Surrey and NortfvEast Hampshire Group. We publish all our eczema infonnalion on the Scrtiety's website. whh receive(l over million visits during the year. with webpages on emdlients. topical sleroKI treatments, eye and ear eczema, hand eczema, pompholyx eczema and scalp eczema especial p¢)pular. We also promote heatth advice messages through our social media ¢hannels. medKa engagement and other exlernal communicatn$. We ¢ontsnued our programme of webinars. working in partnership wrth St John'5 DermAcademy (part of Guy's and Sl Thomas, Hospital. London} tojointty deliver kn events, one focusing on new treatments for eczema and the other about managing ¢hildhcM)d eczema. Our Q4vn webinar in Septemberon topical steroid treatments for eczerna was well attended and thanks are due to Dr Paula Beattie for presenting this. Recordings of several past webinars a avalable to on the Society's social media pages. Our planned work to develop an online forum to prowde peer support for people affected by eczema, and seoping a WhalsApp channel and an instant mossaging on the Sc¢iety's helpline. webstte for advice enquiries, were not taken forward because of competiig pressure on charity SoUrCes. Page 3
NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) TRUSTEES. REPORT {CONTINUEDI FOR THE YEAR ENDED 310ECEMBER 2022 NES membetship scheme National Eczema Society is a membership organisation and we are very 9ralelul to our 2,200 members who support the Society thrtyjgh their annual membership fee and additional donations. Memb&rs receive our membership magazine Exchange. features expert infomiation and news about eczema. Members are 8150 encouraged to attend the Society's Annual General Meeting and ¢onlribule their ideas on the running of the charrty. As in previous years. support for ourcharity extends far beyond our membership and we remain grateful to all our donors. and to those members who conbnue to support us fiAanualty even thou9h they no b)nger have any personal need of our help. Inme frorn the memberth"p herne has flen as the number of members has gr•Jually declined over the years. We took the drfftcult decisKJn lo ve to producing h¥0 issues of Exchange magazine in 2024. rather than the Curn1 quartedy schedule. $0 that costs are better algned with membershtp income. Reprèsenting patient ¥iOW5 As a national patient organisalion for people with eczema. the SOcty plays a kading rde in providing colledive voice to champion the needs of those affe¢ted by the wndrtion. We seek lo improve health outcomes for people wilh eczema by influencing healih polry and partipatIng in groups like the Demiatotogy Council for England and wothing with professional bodies Id(e the Briti$h Asso¢Btion of Dermalotogists IBADI a1 Pr#nary Care Demiokngy Sctiety (PCDS). As a member of the steeriAg group, we contribthed to the rnaior NHS England Demt01c¥JY Outpatient Transfomattm Programme, which developed a range of guNJance to help dermatology healthcare prwders meet the challenges of responding lo seNcefunding pre5SUTes and the disruption caused by Covid. This covered areas like teledernto1ogY and waiting SIs. We also ¢ontbnue to work to raise awareness ol the need for better understanding and representatKyn in demwtob)gy fc people skin of colour. Patient interest and awareness of the %de effeds of tc)pieal steroid medication, and concems about topical steroid withdrawal (TSW). continues 10 9f04V. NES remains actwe in th area. building on our earlier work with the Brrtish Association of Derrnatog1stS to develop a p05rth 5ts1ement on TSW, and our contribution to the Medicines and Healthcare products Regulatory Agency IMHRAI review oftopical Steroid withdrawal reactions. Topul steroid vAthdwrnl is complex and fesearch into the ¢au$es. $ymplom5 and Ireatments is limited. NES wants to see more research in this area. lo supwt evidence- based dia9nosis and treatment approache5. One the challenges is that the symptoms people experience when stopping using topKal steroids can appear similar to those of poorly controlled eczema. These symptoms can be very painful and di$tressin9. The S(Kiety is emphasising the importance of using top1 sterotd treatments safely and effectwety. armj (kner things is Calling for clearer labelling of lopKJ steroids to sh¢x their poterylstrength. We mntinued lo our organisational capaaty to supwrt patient involvement in shaping research. NES is approached regularly by researchers seeking patient views and lo leam from patient experiences. It is $0 enccwjraging lo see such a range of iesearch undeThvay and new treatments in the pipeline, foll0vng 8 bng penod when eczema wa5 largety overlooked. The SOCW is active supporting e¢zema reseaT¢h by participating in study steerin9 groups, promding patient perspectNes for research trials, and working wrth universrties and compans that are a$$e$sing and developing t)ew drug Irealments. We do this to help ensure eczema researth has the greatest chance of success in rinding new lieatments and uttunatety a re. Prqts supported during the year include.. Page 4
NATIONAL ECZEMA socIErY (A Company Limited by Guarantee) TRUSTEES, REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022 A-STAR- UK-lrish Atopic Eczema Systemic Therapy Register BEACON trial- Best System treatnIS for adLrlis with atopi¢ eczema over the long lemi BEACONornics - stJY embedded wthin the BEACON trol inveslvJaling how eczema treatments wo BIOMAP InnovalTve MedlneS Initiabve- in Atopic Dem)at(rtis and Psor$1$ ECO trial- Eczema Care Online END-ITCH trial- Eczema and Oermatitis. Implwxenting The Crynbined APPrh Global Patient InrtiatNe for Optimal Eczerna Care Navoaling primary care with Top1 Ster0 Wrthdrawal RAPID Eczema Trials Programme SLEEP study- Supporting Children's sleep in those with Eczema Progrrne TECH study - Teleconsultalwms for Eczema in Children TRANS-FOOOS study- pre¥entir¥J peanut allergy National Eczema Socth staff and Trustees ccmtrikyJted to several artth5 in xadernic Ijral5 over the year, induding.. Topical steroid withdrawal syndforre.. lThe to bridge gap.. Chantal Cotter et al. BrIth Joumal of Demiolcgy, July 2022 Topical corticosteroid withdrawal." the patient communty call for hvjh quality research, Car definitKJns. and diagmslic criteria", et al. British Joumal of Demptobjy, Laura Well5 et al, November 2022 The souThJ of silence.. where are the v0S of patients in ec2ema guideline development?. Korey Capozza et al". British Joumal of Demioh)gy. December 2022 NES also provides a patient perspective for dintcal guidetine development, the assessment of new eezema trealmenls, and polry Consultatns. During the year. we contributed to the assessment by the National Inslilule of Heatth and Care Excellence INICEI of a nwi monodonal anlibcdy drug called Iralokinumab and hvo JAK-inhibitor treatments. upadacitinib and abwtinib. These new treatments lor m(xlerate to sevefe eczerna were all approved for use by the NHS. We also contribuled lo several drug assessments for the Scottish Medicines consortium {SMCI over the year. As eczema affects people in different ways. it is importanl Ihat we have a range of Iarment options to help ensure people Can acce$$ o treatrrent that works effe¢tNely for them. In other influencing actNity. the continues to work th the Medicine5 and Heafthcare products Regulatory Agency IMHRAI to support the Agency's ¢(nmUntion programme lo raise awane$S of fire risks of emc4b"ents. ErMIlnt pxkaying now comes tP4rth fire wamrng labels. Emollients are not flammable in themselves. or when they are on the skin. H*ever. if bedding, cfolhing or dressings containing dried emollient residue catches fire (from a naked Ilamel. they burn more quickty and tensdy. Awareness raising. communkatlons and umpaigning The charity undertakes a range of athrties to raise awareness arKI understsnding of eczema among the general public, and to prcffnote the information and advvthe Society provides for people living wfth eczema and their families. Page 5
NATIONAL ECZEMA SOCIETY {A Company Llmited by Guarantee) TRUSTEES, REPORT {CONTINUEDI FOR THE YEAR ENDED 31 OECEMBER 2022 ActNity for Nional Eczema INeek in Septemberwas mited due to Cwty constraints and the period of national mouming follw'ng the death of Queen Elrzabeth 11 earlier that month. We intend to turn wbth a strong campaign for 2023. The Scciety prowded press thnmenl for a number of eczema stories in the mgdia over the year. We achieved meThtns on BBC Moming Live and BBC Online, as well as coverage in the Daity Mail. Daity Tdegraph. The Times and i newspaper. on tcpi¢$ ranging fiom tests for babies to predKt eczema risk. lo new treatments and TSW. The Society was also featured in several professional publications induding the Nursing Standard. Capacty constraints and ccrfnpetin9 Priorities tontsnue to impact on the pioactive me<lia work we ale able lo underte. We continued lo gr(xv our social media reach and aclwity during the year, reflecting how people incieasingly seek and share Informaln about eczema. The sIety now has over 24,OCrf) followers on Facebook. an increase of more than 1300 over the year. We also grew ourfolltyving on Twitterto neaty 8,500, and 10,000 on Instagram by the end of 2022. Growing income and building financial sustainability In 2022. we invested more resources in income generalton wilh the appointment of an experienced fundraiser, Sammi Skelding, as Deputy Chief Executive. This refiects our commitment lo achieve our charitable objectives and build futu financial sustainab¢lty. We are immènsely grateful lo our Ihou9htlul and generous supporters who choose to leave a grft to National Eczema So¢ty in their Will. Income tr legacies was much l¢)wer in 2022 and this had a svJnifKanl impact on our overall income, ernstrats"ng the wnportance of wioriiising legw ging act"Mty. We continue to develop partnerships with companies that share our values and are willing to support our work and engage in joint edUK)n and awarenessqaising activty. During the yearAbbVte, Dermal, Eli Lilly. LEO Pharma and Sanofi were 811 corporate nmbers. We are especially grefLI to staff and partners at Swagelok Manchester for their ¢Mtinued generou$ supp There were many fundrai5irffJ hr9hlighls during the year. Incorr from challe.nge everbls. including the London Marathon, was much irnproved in 2022 following the disruptk)n caused by Covid. NES organised several new fundraising events during the year. including the 'May Day March, and 'Cake Bake Donate,, and thanks to everyone who took part and donated. Hang scoped oplitins, we took the decision not to prwRed wih deveknping a product endorsement scheme. We contsnue to find it challenging securing grants from ehariiable tntsts and fourKlation$. The Slety's West Surrey and North-Eas1 Hampshire Support Group Urert00k various local fundraising activities around Guikfford, and Presented a cheque for Q,OW at the Annual General Meeting in September. In addition, group members raised over £600 through taking part in the Guildford Rotary Annual Charity Sponsored Wafx. The Society's members and donors generousty supported our summer and Christmas lundraisin9 appeals once again and we are grateful to everyone who supported the Society in drflerent ways with Ihr donatKJns over what has been a challenging year with cost of Imng pressure5. Organisational development During the year, we started the prcKess of reviewing option$ and planning forthe Society's future oftice requirements. The lease on the charty'5 current Oire expire5 in March 2025 and future provision needs to lake into account changing needs follcming the introduCtn of hybrid workin9 arfan9effnts. Page 6
NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantsèl TRUSTEES. REPORT {CONTINUEDI FOR THE YEAR ENDED 31 DECEMBER 2022 Strategy work urKlertaken included refining the &Kiety's viswi. mi$sb)n and values aTrJ scoping work lo refresh the charity's brand arld Visual identity. We have also posItned our charitle work into three core areas.. Provide infomwtion and advKe Improve eczema care Support e¢m0 research Going forward, we want to give greater relative priority lo awareness-raising. communications and campaigning. where we have Ihe opportunty of helping greatef numbers in the large eczema communty. 2023 Plans and developmenl prforltles Looking ahead, we aim to ensure National Eczema Sctiety continues to achEve the greatest impact we ¢an for members and others INing with eczema. The charity's core ¢haritabk worf( will continue. as well as tsking forward StrateglY important adivty including building our digital capability. our fvndraising. supporting research and strengthening our work to improve eczema care. Development pnorities for 2023 indude: Delwer infoTmatlon and advi¢e Continue providing hIgqUalIty eczema infom)at)n aTrJ a(fve. through the website. winled publications, Helpline, webinars and other channels. Scope and develop resoufces to highlight the impact of eczema on peCy'S mental heomh and emotional well-being. Introduce a regular monthty e-newsletter for NES slakeholders. S¢ope and plan a NES-moderaled online forum and closed Facebook group. Improve eczema care Increase public avrareness and understsnding of the challenges of INing with eczema, highlighting the impact on people's physThl. mental heatth and qualty of life. Lead the annual national flagship awareness event. National Eema Week in September. Develop and lead a coalth.on to campaign for clearer potency labelling of tOPiGal steroids. Continue to enga9e with the topical sterryd withdrawal MmUnitY and call for more research into diagnosis and treatsnent. Contribute patient perspectNes to clinical 9uideline development and the assessment of new Ireatrmenls and polw consultations, working th regulatory bc#J*s induding the MHRA, NICE and the SMC. Support ecz•ma research Scope options for developiro an NES research grant programme. lo fund sludent5hips and innovatton grants for eczema research. Partnef With the UK Dermaldogy Clinul Trials Nthork (UK DCTN) to offer 8 £10,000 award foreczem&related research, as part of Ihe UK DCTN'sjointresearch call for proie¢t$to improve dermatology care lor people with skin of cojour. Recruit a panel of people with eczema to share their eyperierKe5 of living with the conditwjn with researchers. Page 7
NATIONAL ECZEMA SOCIETY (A Company Limited by Guaranlee) TRUSTEES. REPORT {COPINUED) FOR THE YEAR ENDED 31 DECEMBER 2022 Continue to contribute patient insvjhts for maicw eczema research projects and programmes. We also have a number of initiatives planned to grcyw charity NOMe aThJ build organtsational capability in 2023. Flnanclal Results The So¢iety planned for a deficit budget in 2022. atthough the Ported figure is larger than anticipated. It is disappointing lo experience Ihis def1t in 2022 after &hieving an operating surplLts for s&veral prior years and rebuilding reserves to a stronger P)5rtn. The weaker 2022 result 15 largefy d¢)wn to lower than expected income from kgary gffts. Income for the yearwas £342,821. with expertditure at £413,759 ar an annual deficit of £70.621. This compares wrth a surplus of £185,322 in the year ended 31 Drfember 2021. AI 31 Oecember 2022. the ScLiety had reserves of £651.070 (£721.691}. We would like lo Ihank the many people vtr. as in previous years, by joiniNJ or renewing their membership, supporting our appeals an¢J fundraising in a variety of often innovative ways. have enabled us to continue our work. The efforts and contrut)n of supporters and volunteers is invaluable to the Society. We are grateful also to those who remembered the SOcty in their Wills, the charitable trusts and companies th have svpp)rted us during the year. and to all the heatth¢are professionals who have provided u5 With so much time. a¢lice and $upFNt especialfy members ol the Medical Advisory Board. Reserves Policy The trustees aim to maintsin adeque reser¥es to pemil the on90ing ¢)perations of the chartty. In arriving at their assessment of a suitable limit. trustees have COnsed the. pdIctabIlIty of the Society's income and the nature of rts expendrture, together With the degree to which these are committed. Legacies form an important part of the Society's income. and whilst legacies can often be subslanliaj relatNe lo overall income, they are Unpdble and historical trends shcw there can be periods of years Whe this source of income is much kmer than the long-tem average. Expendrtu on tho other harHI 15 more con5iStent and predictable. Trustees last reviewed the Reserves Pol¢cy in 2022. and consider that holding unre51rrted reserves equal lo approximatety six rIth$ unStriCted Charitable expendrture would be Sulficient to close or merge the charity, shoukj this ever be necessary. However. gNen the known vokllity oflegacy income. tNstee5 have detemiined a re5erve5 target of 12 months. future overheads expendrture is more appropriate to respond to fltU1$ in inco. In order to make unrestrKted reseNes more transparent, fiJnd5 that are not adity avaiLable to spend are held in reserves designated for 5pecfft purposes. A key aim of the Society 15 to promote research inl¢ the causes and treatment of eczema. Th¢5 being $0, the trustees have designated a proportion of reserves to fund future research ¥tivty. in addrtKJn lo any fijnds that d(or5 have $pe¢ifically reStled for this purpose. Fvnd5 that are not readily available to spend. notabty those represented by fixed assets, are hekl in a reserve desNJnated for this purpose. The pension reserve shows future deficit payments owed in relation to an historical defined benefjl pension eme (see note 19). The balance held in unrestricted funds al 31 Deftber 2022 £644.319. Unrestricted funds include funds lied up in tangible assets 01 £19,721. the pension reserye of (£8.5871 and designated Research funds of £110.000. The remaining general funds of £523.185 are materially in line wrth the charty's Page 8
NATIONAL ECZEMA SOCIETY IA Company Llmited by Guarantee) TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022 reserves policy target of 12 months firture overheads eypenditure. budgeted at £525.000 for the 2023 financial year. Risk Management The trustees have taken sleps to identify and add5 major risks facing the Siety. in¢luding maintaining a risk register. The principal uncertainty in reSpt to the Society's future is the ability to maintain sufficient income to deliver the ¢hariVs services. and ensure the So¢ty has adequate resources lo cornpty with re9ulalory changes affecting the voluntary sector. Greater focu5 and investment are being directed tofundraising actwities. to ensure the generates sufficient income each year to fund pknned actNrtS. The financial OLrttum for the 2022 financBI year emphasises the importance of building sustainable sources of non-legacy Inco. The principal risk of financial sustainabilty for the charity is cthety monitored by Ihe trustees on a regular basi5, including revIng management accounts al quarterty Board mtsngs. Attenth)n also ontinues to f$ on rK)Trfinan¢ial risks including healih and $atety. reputation. se¢urty. nfidentia1rty. and data proteclion, whh are supwted by appropriate and procedures as well as management updates as needed. Inv•stm•nt Poll¢y All surplus ore currenlty placed on deposit The Trustees and Oryanlsation The Sc¢iety is a charitable company. Althoygh cailed trustees. we are the directors of the coThyany for the purposes ol ccrtnparty Iw. The trustees who seNed during the year and up to the dae ofthis report are given on page 1. The Society's goVernae processes are set out in its Arte5 of Association. The Board of Trustees administers Ihe Siety. whKh meets routinety four times a year and ad(liticffially as Circumstances demand. A chief executNe is appointed by the trustees to manage the day4trday operations of the Society within a framework agreed by the Board. There must be a minimum of the trustees but there is no maximum number. and tfustees must be eleeled by the member5 oflhe Society at rts Annual General Meeling IAGMI. Trustees may be Cctropled onlo the Board during the year and must then stand for election by the members at the next AGM. At least a Ihird of trustees are required to rekn"refrom office each year but may, rfthey wish. offer themsefves for r&election at the AGM. Trustees a recruited through the So•'s membership. local support groups. other eczema communty neorkS and open advertising. In seeking trustees. the sO¢ty has ard of the need lo ensure that the Trustee Board has an appropriate range of professional skills and experience, reflects our ¢ommtr*nt to divefsity, and also thal trustees a drawn from diffenI areas oflhe UK. Although not constitutionally binding. the So¢igty she5 lo work towards aligning wtth the Charity Govem8n¢e Code, which recommends tru51ees serve fixed lemis in 0e. The guidance recmimends Iruslees serve an initial threfryear temi, with the possibilty of being reelected by members for a further Ihree-year period. Trust in partular lo$ {e.g. Chair. Treasurer) could seNe a longer nine-year period, subject to fomial review. One Cyrnt tN$tee has seNed bnger than nine years and provides specifi¢ professional skills lo Ihe Board. As yet. it has not been possible to find a repla¢effent with comparable expertise. Page 9
NATIONAL ECZEIIA SOCIETY
IA Comp#ny Llrnw by Gu•rnnt••l
TRUSTEES, RepoRT ICONTINUEDI
FOR THE YEAR ENOED 310ECEMBER 20
New trustees a pThbJèd wtlh an ldJ1)n , wdeS the sety's 9oveming
documents. coptes ol the past years aCnts, and 8 biiefing on lhe duties and m$&bIrrts an
of Ihe Sotsety's gwemanc8 proce. Prior to Ihe Board. new tW5tees wll UallY amend at
leastone Boaft1 meetin9 in an obseprrspacdy. Tmtach ws them to Thet Ihe tru$ts8S
and thief eX1ve.
Trustées re¥9 renwftwai and M tBtee has a bel intern51 In any ol ts group
cornpanies.
The sOty has a PAerfica Advw Brwd IMA81, c
IIATIONAL ECZEIAA SOCIETY IA Company Umll•d by Guaranl••l STATEMEIIT OF TRUSTEES. RESPONSIBILITIES FOR The YEAR ENDED 310ÈCEMBER 2022 The Tw5tees (who a atso the ijiredots of the Chanty for fv w•5 of company lawl arn fo$pJnsible for syepaty the Trustses, Reimyt ar Ihe stsments ift accor wih aFplit4ble 18w and Unrted KIvJtJom AOUnts"rj Slandards (Uniied Kingdryn Gew811 Acwled Accwntirq Pfacttcel. CcfftpaThy requ¥es Ihe Tnxtees tr) Yep8 ffirw¢ial staternertls lor each finanrial YEW. Undef company law. Ihe Trusleos musl Th)1 awrove ts ffinartial staieirnts unless they are satisfied I11 they giv8 a tnJe and lair ew ol Ihe ol aTrdirs of thE .Group ar4J Chanty and of their inwTUry fESOUm appltim of ourtes. inclwjing thew in)me perK•J. kn preparirY4 t1 fiftawal statents. the Trttee$ a requi lo.. obseN• thè rrll(l5 and WHpIeS ofthe crliS SORP IFRS 1021.. make judgemènts artl a¢c¥)unkng è5b"mates that ar• reason•tl• aThl pDJ(. stste whelher appticai4e UK Acclyuthg StarKlards IFRS 1021 hava been Ic4krwed. suti•¢t to any mal•rial departu$ disdos•d ar e¥fAain•d in the financial $eMents. Pfeparè the financaal stai¢rnenls on going v)n¢wn basi5 unless it is inaPFwiat¢ to pr•swne thal thè Tha Truste ara respJn8itle lor keeping adoquate tirj records tst am suffi(xènt Sh¢ and 8Wain th& Group and tho Charitys traitsxkn and disdose w41h reasonatslè acoJrn¢y at any time Ihe finafioal w5ib.on of Group ar#Y the ChaTrty •nablg them to eTh5u thai th• fmanr Slotgments ¢uJmpty with the Cornpanies Act 2C¥)6. They are also rt%(t)nsl)le f<¥ safeguarylirvj the ass6ts 01 Ih? Group and th? Charity and hence for lng reasonW¢ steps for Ihe weven11 aThl detectiM offraud and olher iThegularilies. Appwed by ol Ihg Memtrs (rfthe 8od of Truste signed b6t*W ty. St•ph¢n Pugh Chair Dal•'. 7th Seplember2023 Pagè11
NATIONAL ECZEMA SOCIETY (A Company Limited by Guarant¢e} INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2022 Indepèndent Examinerf$ Report to the Tntstees ol Natlonal Eczem• Socl•ty llhe Group'} I report to the Charity Trustees on my examinatK)n of the consolidated w)unts of the Group. set out on pages 14 10 45. comprising the National Eczema (Ihe parent Charty) and rt5 5ubsidi¥y undertakings for the year ended 31 ernber 2022. Responslblllties and Basis of Report As the Trustees of the parent Charity land its Directors the purposes of company lawl you are responsible for the preparation of the consolidated accounts of the Group in accordan with the requirements of the Companies Act 20[ ('the 20[ Act.). Havsng satisfied myself that the eonsolNJaled aecounls a not requId to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Group'$ ac¢oLtnts as carried out under section 145 of the Charitie$ Act 2011 Cthe 2011 Act'l. In carrwng Out my examination I have followed the Direth"ons gNen by the Charity CoMmissn under Section 145ISllbl of the 2011 Act. Independent Examinerfs Statement Since the Group's gross income exceeded £250.OC(l examiner must be a member of a bc•Jy listed in section 145 of the 2011 Act. l ¢onfim that l am qualffj*d lo undertake the examination because l arn a member of the Inslitule of Chartered Accountants in Enuqand arKI Wa. whKh 15 one of the listed bodies. I have completed my examinatThi. I confimi that Th) matters have come to my attention in conneclK)n with the examination giving me cause lo bdwe in any material sPecI.. accounting records were not kept in respect of the parent Charty its subskliaries as required by se¢tion 386 of the 20CIS Act.. or the accounts do not accord with those records: or the accounts do not ¢ompty th the accounting requirements of section 3% of the 2006 Ad other than any Tequirement that the accounts give a Irue and fairf Vie•V which is not a matter considered a$ part of an independent exaMinatn.. or the accounts have not been prepared in accordance with the methods and principles of the Stslement of ReCoended Practice for accounting and rep'n9 by chartties applicable to thaiilies pparing their accounts in SeIan th the Financial ReIng Standard applubte in the UK and Republi¢ of lftsand IFRS 102). I have no concems aftd have tome across no other matters in eonneetion wrth the examination to which aliention shoul¢J be drawn in this report in order to enable a proper understsnding of the ants to be reached. Page 12
NATIONAL ECZEMA SOCIETY IA Company Limited by Guarantee) INDEPENOENT EXAMINER'S REPORT ICONMNUED) FOR THE YEAR ENDED 31 DECEMBER 2022 Signed.. Dabj: 11109r2¢r23 Stuart McKay Bsc FCA DChA MHA Chartered Accountants London. United Kirwom Page 13
NAnoNAL ECZEMA SOCIETY IA Company Limited by Guardnteel CONSOLIDATED STATEMENT OF FINANCIAL ACTIWllES IINCORPORAnNG INCOME AND EXPENDITURE ACCOUNTI FOR THE YEAR ENDED 31 DECEMBER 2022 Unrestricted funds 2022 Restr5cied funds 2022 Total funds 2022 Total funds 2021 Not• InCle from". Donations and legacies Other trading activities.. Income from furKlraising Income from trading acliwties Investments 322.062 6.013 327,075 528,134 10.205 4.109 1,432 10.205 4,109 1.432 4,921 1.801 856 T¢)tal income 337.808 5.013 342.821 535.712 Expenditure on: Raising futKI$ Charrtable adivities 64.906 348.853 32.804 351,725 Total expenditure 413.759 413,759 384.529 Net movement in funds before ¢)ther recognised gains 175.951) 5.013 170.9381 151,183 Other r¢¢¢gnised gains: Gainslllossesl on pension scheme 19 317 317 34.139 Net movement In fvnds 175.6341 5,013 170,621 185,322 Reconclllatlon of funds: Total funds brought f¢)rward Net rTr)vemenl in funds 719.953 (75.634) 1.738 5.013 721.691 (70.6211 536,369 185,322 Total funds carri•d forward 644.319 6.751 651.070 721,691 The Consolidated Statement of Financi Ath"vibes inclth all gains and losses rwniged in the year. All income and expenditure defive from ¢ontinuing activits The rte5 on pages 20 to 45 form part of these financial st*mnts. Page 14
NATIONAL ECZEMA SOCIETY {A Company Umiled by Guardnleel REGISTERED NUMBER: 02685083 CONSOUDATED BALANCE SHEET AS AT 31 DECEMBER 2022 2022 2022 2021 2021 Flxed assets IntangiTrAe assets Tangible assets 14 1.836 17.88S 8.832 27.886 15 19.721 36.718 Current assets Debtors". Amounts falling due within one year Cash at bank and in hand 17 65.445 687.108 159,515 649,260 752.553 808.775 Creditors: Amounts fauing due w*hin one year 18 (115.0281 Nel current assets 635,613 693.747 Total assèts le$$ curent liabillties 655.334 730,465 Credrtors.. Amounts falling due after Ire than one year 19 {4.2641 18,7741 Totsl net assets 651,070 721.691 Group funds Restricted funds unstrICted fvnds 20 20 6.751 644,319 1.738 719.953 Total funds 651,070 721,691 The Charty was entiw lo exemption from audit under se¢lion 477 ofthe Comparties Act 2006. The member$ have not required the company to obtain an aLwJit for the year in question in accordance with section 476 of Cc4npanies Act 2. The Trustees ackn(swledge their reswnsibilities for comptyry with the requirements of the Act wilh respeet to counting records and preparathw of financial ststements. The financial statements have been prepared in aOrdae with the provisions ¥plicable to entities subject to the small companies regime. The financial Slalemenls were approved and aulhorised for issue by the Twstees and signed on their behalf by. Page 15
NATIONAL ECZEMA SOCIErY IA Conyany Llfflit•d by Guarwrt•¢) REGISTERED NUM8ER: OWSIX3 CONSOLIDATED BAIJMCE SHEET IC014TINUED AS AT 31 DECEMBER 2022 Jam•$ Pltoyaftukl Trea$urw Dale.. 7th September 2023 T notes on Pa9 20 to 45 fom part of fvwnry¥l st81•. Pag• 16
NATIONAL ECZEMA SOCIETY (A Cornpany Limited by Guaranttel REGISTERED NUMBER: 02685083 CHARITY BALANCE SHEET AS AT 31 DECEMBER 2022 2022 2022 2021 2021 Note Fixed assets Intangible assets Tangible assets Investments 14 1.836 17.885 11)0 8.832 27.886 100 1S 16 1921 36,818 Current a$$ets Debtors". Amounts falling due within one year Cash at W and in hand 17 131652 647.526 211,072 624,435 780,178 835.507 Creditors.. Amounts faI"n9 due within one 18 (115.140) (113,2281 Net Current assets 665.038 722.279 Total assets less current liabilities 684.859 759,097 Creditors." Amounts falling due after mo than one year 19 14.264) 18.774) Total net assets 680.595 750.323 Charlty funds Restricted funds UnrestTKted funds 6,751 673,844 1.738 748.585 Total luTrd5 680.595 750,323 The Chariirfs net movement in fvls for the year was £(69.728) {2021- £188.521). The Chaiity was entitled lo exempkn from alIt under section 477 oflhe Ccffipanies Act 2006. The members have not reqLFired the c(Mnpany to oblain an audit for the year in Questn in accordance with section 476 of Companies Act 2006. The Trustees acknuwledge their responsibilities for cOmpln9 wrth the requirements of the Act with respect to accounting records and preparation of financial 5tatwnents. The financÉal statements have been prepared in a¢>[dan with the provisions applble to entities subjed lo the small companies regime. Page 17
IIATIONAL ECZEMA SOCIETY IA Company Llmlt•d by Guarnnt•*l REGISTERED NUMBER: 026B50B3 CHARffY BALAMCE SHEET ICOMTINUED) AS AT 310ECEM8ER 102Z Th? ffironu31 #•tem8nts apwov¥d aFKI is8 bytht Twste•s and on b•Mf by.. James iilt4yanukul Treaslrtr Date.. 71h Seplember2023 The not•$ ffi page$ 20 to 45 fowm port ofthese stalwnerts. Page 18
NATIONAL ECZEhiA SOCIETY {A Company Llmited by Guarantsel CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2022 2022 2021 Note Cash flows Irom operating a¢ll¥ltios Net cash used in operats.ng activrt 36,416 52,795 Cash flows from Investing a¢tivitie$ Investment income Purchase of tangible fixed assets 1.432 856 15 {2.146} Net sh provided byllused In) Investing activities 1.432 (1.290) Change in cash and ush ¢qul¥alents In the year 37.848 51,505 Cash and cash equNalenls at Ihe beginning ofthe 649.260 597,755 Cash and cash equNalents at the end of the year 23 687.108 649.260 The notes on pages 20 10 45 fomi part of these financial *atemenls. P4e19
NATIONAL ECZEMA SOCIETY (A Company Limit by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 310ECEM8ER 2022 General Inforniation National Eczema Soa"ety is a Charitable company INTWted by guarantee and is registered th the Registrar ol Companie5 (Cunpany Registered Nurnber". 026850831. the Charity Commission in England and Wales (Charity Reg[sted Number." 10096711. The Chwity dewi8tered from the Office of the sttISh Charity Regulator (OSCRI w 15th Ocl()er 2021. In the event ol the Charity being wound up. the lilIrtY in respect of the guarantee is lynited to £1 per qefnber of the Charity. The addsS of registered offKe is given in the Charity inf0mtiOn on pa3e 1 of these financi81 statements. The nature of the Charitys operations and prin¢ipal ¥tivthes are detailed in the Trustee$. Report. The signtfi¢ant xccwnting W)le5 4Jplied in the preparath?n of these financial $tstements are sel. out below. These policies have been consistenty appliod to all ye¥s presented unless otheiSe stsled. A¢¢ounting poli¢i•s 11 Basls of preparatlon of financial statements The finanaal Statents have been prepared in accordance wlh the Chariknes SORP IFRS 102) - Accounting and Repoth"ng by charrtS'. Statement of Recommended Prart applicable lo charf(ies pparing their a¢ntS in wxordan¢e the Finanoal Reporting Standard applicable in the UK and Republic of Ireland {FRS 1021 and the Companies Act 2006. Nali¢)nal Eczema s meets the definition ofa publ benefit enlty under FRS 102. Assets and liabl1rt are inibaly recognised al historical ¢ost or transadion value unless othemise Stated in the relevant accounbrvj poliw. The ConsolKJaled SeMent of Financial AIAiwts (SOFA) and Consol#Jated Balance Sheet consolidate the finanal ststwnents of the Charity and its subsidiary undertaking. The results of the subsidiary are consc4hJated on a line by line basis. The financial statements are prepared n sterling thich is the fundional and pre5entstional currency of the Grp and a rounded to the rst Frt)und. 2.2 Golng concern The Trustees have assessed the use of gOg corKem and have considered possible events or conditions that might cast signficant doubt on the ability of the Group to continue as a going concern. The Tnjslees have made this assessment for a periDJ of al a$1 one year from the dale of the approval of these finan¢ial statements. The Truslees have concluded that there is a reasonable expectation that the Group has adequate resource5 to continue in operational existen for the foreseeable future, and that rLO material unrtain"es extsl. The Group therefore continues lo adopt the g¢yng concem ba515 in preparing these financial 5tstements. Page 20
NATIONAL ECZEMA SOCIETY IA Company Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Accounting policies Icontinuedl 2.3 Incorne All income is recognised once the Group has entitremenl to the income, it is probable that the income will be received and Ihe amount of income receivab can be measured reliably. For donalrons and grft aid to be fecognised the GT¢JJP wll he been notffied of Ihe amounts and the setllement dale in wrrting. If there a condthons attached to the donatK)n and this requi$ a level of perfomance before entthmenl can be obtained then income is deferred until those conditions are fvlly met or the fulfilment of tlv)se COndOn$ is yh1n the control of the Group and it rs probable that theywill be fuifilW. The recognition of income from aeS is dependent on establishirvJ enlrtlemenl. the probats.lily of receipt and the abilty to estimate wth suffiCnt accuracy the amount receivable. Evidence of entillemenl lo a legacy exists when the Group has SLtffKienl emdence that a gift has been left to them {Ihiough knowledge of Ihe e$ten of a valid wll and the death of the benefaclorl and the executor is satisfied that the property in question will not be required to satisfy ¢laim$ in the estate. Receipt of a legacy must be COgnised when tt is Probab that it will be received and the fair value of the amount receNable. whh wiu generally be the expeded cash amount to be distributed lo the Group, Can be relrably measured. Subscription income is received in fun and recr•Jntsed evenly over the course of the sth)scriplton. The amount reccgnised in the Consolided stennI of Financial ActivitS relates to the financial period in question. Income from trading activrties ineludes irtome eamed from fundraising events and trading activities to raise fvnds for the Group. Incrxne is received in exchange for SuPplng goods and services in ¢yder to raise fvnds and 1$ rewnised wthen entsdewnl has Tred. 2A Expenditure All expenditure is accounted for ac¢nMls basis and has been ¢lassified under headings that aggr8gate all costs related to the categories. Expenditure is reccfvsnised once the is o legal or constructive obloation lo transfer e¢oncthi¢ benefft to a third paty, it is probable that a transfer of econrxnic benefits will be iequiied in settlement and the amount of tho obligation Can be measured reliably. Expenditure is classified by adimty. The ¢ost$ ol each aclivty are made up of the total of direct costs and shared costs, including support ¢o$t$ invcAved in undertaking each aclNity. Oirect costs attributable to a single activty are allocated directy to that activity. Shared costs which contribute to more than one actiwty and SUppt costs which are not attributab to a single activity e apportioned befvleen those activit5 on a basis consistent the use of resources. Central Stsff C0515 are alloGaled on the basis of kn.me spent. and deprecial¥)n charges allocated on the portion of the asset's use. Expeniture on charitable acli¥its is incuffed on directty undertaking Ihe aclmties whKh further the Group's objectives. as well as any associated SUFVOrt costs. Al expenditure is indusive of irreo)vernbbe VAT. Page 21
NATIONAL ECZEMA SOCIETY IA Company Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Accountin9 policies (continued) 2.6 Interest recelvable Interest on funds held on deFQSit is included when re¢etvable and the amount can be measuffjd reliably by the Group,. this is nomially upon nolifi¢ation of the Inte$t paid or payable by the institution wtth whom the funds are depostted. 2.6 Taxation The Charity is c¢msidered to pass the tests set out in Paragraph 1 schedu 6 of the F¢ance Act 2010 and therefo (( meets the definit) of a charilable company for UK corporation tsx purposes. Acwrdingty, the Charty is F4)tentially exernpt from ts¥ation in respect of in¢ome or p11 gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Sectton 256 of the Taxatson of Char9eable Gains"Act 1992.. to the extent that such income or gaS are applied exclusivety lo charrtable purposes. 2,7 Intanglble assets and amortlsatl¢>n Intangible assets costing £500 or more a capltslised and recognised when future economic benefts e probable and the eost or ¥ue of the asset can be measured relHbly. Intangible asset$ are initially rQgnised a¢ cosL After few3n1¢)n, under the cost m¢>Jel, intangibl assets are measured at cost less any aUMulated amoitisation and any xcumulated impairment k)sses. Amortisalion is provided on intangible assets at rales cakulated to write off Ihe cost of each asset on straNJht4ine basis over 3 years. Assets under eonstruction are not arnortwd until ready for use. 2,8 Tanglble fixed assets and depre¢lation Tangible fixed assets costing £500 or m¢ye are pItalISed and re¢ognised when future eOMiC benefits are probable and the cost OT value of Ihe asset can be measured reliably. Tangible frxed assets are i"aNY reeognised at cost. After rec¢)Jnition, under the cost model. tangible ffixed asset$ a MeasUd at cost less accumulated depreciation and any accumulated impairment k)sses. AN $t$ in¢urred to bring a tangible fixed asset into it5 intended workin9 condition Should be included in the measurement of cost At each tIng dale the Group assesses vllthr there is arry indication of impaimient. 11 such indication e$1$. the t)verable amount of the asset is detemiined lo be the higher of its fair value less ¢ost$ to sell and its value in use. An impaimient loss is rec¢)3nised where the carrying amount excegds the ro¥erab amunl. Page 22
NATIONAL ECZEMA SOCIETY {A C¢mpany Limlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Accountlng policies {contlnued 2.8 Tangible fixed assets and d•prKiatlon {continu•d) Depreciation is charged so as to allocate the cost of tangible fixed assets less their residu81 value over their eslimated useful lives, using the straigh14ine method. Deprecialion is provided on the fo1[ing bases: Leasehold improvwnents Furnitu and frttings Office equipment Computer equipm8nl - over 10 yeafs - over 10 years - over 10 years - over 3 years 2.9 Investments The investment in the subsidiary C(panY is valued at cost less provision for impaim)ent. 110 Debtor5 Trade and other delkns ao reeognised at the settlement amcwnt after any trade discount offered. PrepayThents are valued at the amount prepaid net of any tr* discounts due. 2.11 Cash at bank and in hand Cash al bank and in hand includes ¢a$h and short4emi hohty IU investment$ with a short malurty of ttwee months or less frc¥n the date of acquisikn.on or opening of the deposit cf similai account. 2.12 Llab511tl•s and provlslons Liabilities are reco9nised when there is an obligatn al the Balare Sheet date as a result of a past event, it is probable that a transfer of economic benefit w1 be required in SettMent, and the amounl of the settlement can be eSb.rrted reliabty. Liabilities are recognised * the amount Ihal the Group anticiiates will pay to settle the debt or the amount it has received as advanced payynenls for the g¢)ods or Se1 il must provide. Provisions are measured al the best e$bmate of the arrKJunts required to settk the obligation. Where the effed of the time value of money is material. the provision is based on the present value of those amounts, discounted al the pre-tax discount rate that refle¢ts the risk5 specific to the liability. The unwnding of the discount is reeogrrfsed in the consorated Statement of Financial Adivities as a finance cost. P•38 23
NATIONAL ECZEMA SOCIETY IA Company Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Accounting poll¢l¢s {¢onllnued) 2.13 Financlal Instruments The Group only holjs basic Financial Instruments. The financial assets and financial liabilit5 of the Group a as fdh)ws: Debtors - other debtors a basic fmancial instruments and are debt instruments measured at amortised cost as detsiled in Note 17. Cash * bank- is ¢la$$ified as a basi¢ finala1 instrument and is measured al la value. Liabilities - accTua15 are daSSif as financial instruments. and are measured at amortised cost as detsiled in Notes 18 and 19. 2.14 Opgrating leases Rentals paid under cperab"rrfJ Se5 a char9&Y to the c0nsolhed Statement of Financial ActNities on a stravJht line basis over the lease lemi. 2.15 Pensions Through its past partiapatw. the Group has a liikty to a pension scheme calkd Ihe Series 3 Groyrth Plan, whh dosed in 2013. Since then, the Group has participated n a defined contribution pension sd)eme for empknyee5. operated by W0P1aCe pension provider TPT. The Group is part of the Series 3 GrTh•hh Plan which is a mUltP10Yer pension Scheme vthi¢h closed in 2013. The Scheme &Jministralors have confirmed that il is not Possible lo separately identfy Ihe assets and liabilities of participating employers on a ¢Msistent and reasonable basi5. The assets of the Scheme are co-min9led for investment purposes and benefits are paid from totsl Scheme assets. A deficrt redUCtn plan has been agreed. The Group accounts for its participat# in this Plan as a defird conliibulion plan, a5 there is insufflent infomiatKJn available to a¢Unt for this as a defined benefft plan, as the share of ils assets and liabllrtS cannot be klentified. To evtyd ¢rystslliiro an imrnediale payment of the apparent under-fijnding in the Sefies 3 Scherne, the Group is participating in the Series 3 ReVery Plan arKI the liabilty is inGluded in Notes 18 and 19. The GrcyJp reccJnises its liability to make payments to ftjnd the deficit relating to past seNice under an agreerrEnl lo make those payments. 11 recognises the full liability for the present value of ¢ontributions pay*>le that results from the agreement for fvnding the Mu1 empk)yer plan. The Group also participates in a defined contribLrtion pensicm scheme for its employees. Thg Group pays fixed eonlributK)ns inlo a separate scheme. Once the deffined Contribution payments have been made, the Group has no fijrther payment obligation5 in respect of this sCherr. The contributions are recognised as an expense Cated Stslement of Firbancial Alt$ as they fall due. Page 24
NATIONAL ECZEMA SOCIETY IA Company Llmited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Accounting policie5 {continued) 2.16 Fund a¢¢ounting General fvnds a unrestricted funds whrch a awlable for use at the disuelion of the Trustees in furtherance of the general rtijecb.ves of the Group and which have not been designated for other purposes. Designated funds comprise unrestricted funds that have been sel aside by the Trustees for particular purposes. The aim and use of each design*ed fvnd 15 Sel out in the notes lo the financial slatements. ReStrted fvrK4s are funds whi¢h are lo be used in accordan¢e with Specif restrictions imposed by donors or which have been rnised by the Group for particulaf purposes. The costs of raising and administering su¢h furtds are charged againsl the specific fund. The aim arvj use of each restricted fund is sel out in the notes to the finan¢ial statements. Investment income. gains and losses are ano&ited to the appropriate fund. Critical accountlng estimates and ar8as of judgement Estimates and judgements are continualty evaluated and are based on histor1 experience and other factors, including expeclations of fvture events that are believe(I to be reasonable under the circumstances. Cntical accounting estimates and assffjK¥ns'. The Group makes estimates and assumptions con¢eming the future. The resulling accounting estimates and assumptions will, by definrtion. seklom equal the related actual results. The eslimales and assumptions that have a Snlcant risk of causing a material adjustment to the carrwng amounts of as$ and liab1b.e5 within the next fintrtial year are list be. cation of support costs Legacy income recognition Depreciatn rates for tangible fixed assets Useful economK lives of assets The discount rate used in valuing the rnd Pens¥)n Scheme defKit. Page 25
NATIONAL ECZEMA SOCIETY (A Company Limited by Guarants¢l NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDEO 31 DECEMBER 2022 Income from donations and lega¢l•s Unrestricied R•strlcted funds funds 2022 2022 Total funds 2022 Donations arKI similar income Legacies Subscriptions Grft aid 132,853 24.7C6 143.952 20.551 5.013 137,866 24,706 143,952 20.551 Total 2022 322.C62 5,013 327.075 Unreslricled fvnds. 2021 Totsl funds 2021 DlatIOnS and swnilar income Legacies Subscriptsons Gift ald 174,348 181,302 150,978 21.506 174.348 181,302 1 50.978 21.506 Total 2021 528.134 528,134 P¥Je 26
NATIONAL ECZEMA SOCIETY {A Company Llmlled by Guarantsel NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Income from other trading activllles In¢ome from fundralslng events Unrestricted lunds 2022 Total funds 2022 Other corporate income Other activities 6,265 3.940 6.265 3.940 Total 2022 10,205 10,205 Unrestrict fvnds 2021 Total funds 2021 Other corpor*e income Other ath'wtses 1,607 3.314 1.607 3.314 Total 2021 4.921 4.921 In¢ome from non Charitable trading activities Unrestricted funds 2022 Total funds 2022 Trading Subsidiary 4,109 4.109 Unrestricted funds 2021 Total funds 2021 Trading Subsidiwy 1.801 1.801 Page 27
NATIONAL ECZEMA SOCIErY (A Company Limited by Guarantv) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Income from inY8sbrnnts UnTrstri¢ted funds 2022 Total fund$ 2022 Bank interest receivable 1,432 1,432 Unrestricted funds 2021 Totsl funds 2021 Bank interest receiwable 856 856 P•3e 28
NATIONAL ECZEMA SOCIETY IA Company Limited by Guarantsel NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Expenditure on raising funds 2022 2021 Fundralsing Costs Direct costs Support costs 59,330 5.574 27,431 5,373 64.904 32,804 Analysis of support ¢osts- fundratslng costs 2022 2021 Staff costs Depreciation Premises costs Carriage and postage Professional fees Boughl-in seNces Website, database and computing Other costs Govemance ci>sts 1,735 562 727 1.539 683 779 174 560 30 541 289 370 33 583 931 700 387 5,574 5.373 2022 2021 Trading costs Trading subsidiary- Direct costs In both the current and previous financial years all Expendrture on raising fuTrJs was from Unrestitled fvnds. Page 29
NATIONAL ECZEMA SOCIETY {A Company Limited by Guarantee NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Anatysls of expenditure on Charitab acifvities- by fund Unrestrlcted funds 2022 Total 2022 Helpline Membetship servtes Infomiation seN 100,310 174,303 74,240 100.310 174.303 74.240 Total 2022 348,853 348.853 Unrestricted fund5 2021 Restricted hjnds 2021 Total 2021 Helpline Membership seryi¢e$ Infomalion services 106.899 160.938 73.138 106,899 160,938 83,888 10.750 Total 2021 340,975 10,750 351,725 Page 30
NATIONAL ECZEMA SOCIETY IA Company Llmited by Guardnteel NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEhlBER 2022 Analys of •xponditur• on charitable activities. by tylMI Activities undertaken directty 2022 Support costs 2022 Total funds 2022 Helpline Membersh¥* servirE5 Infomiation services 56.071 .182 33.519 44,239 78.121 40.721 100,310 174.303 74.240 Total 2022 185.772 163,081 348,853 ActNities undertaken dir&tly 2021 Support costs 2021 Total furKIs 2021 Helpl Membership sa8$ Infomation serwces 64.245 85.626 44.631 42,654 75,312 39.257 1,899 160,938 83.888 Total 2021 194.502 157,223 351,725 Page 31
NATIONAL ECZEMA SOCIETY (A Company Limited by Guarnntee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDEO 31 DECEMBER 2022 Analysis of expenditure on charitable adivities- by type (continued) Analy5 of support costs Total funds 2022 Total funds 2021 Staff ¢o$ls oepreatft Premises costs Carriage and postage Professional fees Bought-in services Website. database and ccrfnputs.ng Other costs Govemance costs 9).750 16.435 21.266 8.468 10.838 962 49,310 18,645 21,884 4,888 15,743 845 17.050 27.236 10,076 15,212 19.819 10,877 163,081 157,223 10. Govomance costs 2022 2021 lTrJeperKlenl Examinefs remuneraltty) Rent & rates Insurance Recruitment Room hire & Confwence expenses TTu5tees expenses Travel. hotels & subsistence General ¢)ffi¢e expenses 2.000 5.505 16701 6,386 6.681 1.150 60 198 96 43 10.420 11.264 Total Governanee costs above comprise £344 (2021- £387) of Expendrture on raising funds ond £10,076 (2021- £10.8T7) of EyperHJrture on charrtabje actMti"e5. Page 32
NATIONAL ECZEIAA SOCIETY (A Company Limited by Guarantee} NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 11. Auditors. and Independent eMineS remuneratlon 2022 2021 Independent Examinefs rwmuner*ion- Examination of the financial slalements 5.010 13.0101 6.03 (4951 IrKlependent Examinerfs remuneration- prior sear over-accrual 12. Staff costs Group 2022 Group 2021 Charity 2022 Chanty 2021 Wages and Salaries Social security cosls Pension costs 203.865 18.600 8,470 159,739 13,7 6,857 203.865 18.600 8.470 159.739 13,067 6.857 230.935 179,663 230.935 179.663 The average number of persms employed by the Charty dumg the year was as folkws.. Group 2022 No. Group 2021 No. Direct charitable admties Fundraising and ¢rmmmi¢ation Support and govemarKe The number of employees vhwe employee beneffts {exclj1n9 employer pension ¢o$l$) exceeded £60,000 was.. Group 2022 No. Group 2021 No. In the band £60.(K11 - £70.000 The total amount of employee benefits, indudirvJ employers nalh)nal insurance and pension contributions. receNed by Key Management Personnel is £72.726 (2021 £72,305). The Charity consKlers its Key Management Personnd ¢CPrise the Trustees and the Chief Executive Offir. Page 33
NATIONAL ECZEMA SOCIETY IA Company Limited by Guarnntee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 13. Trustees. remuneratlon and expenses During the year, no Trustees recewed any rernuner*n or otlw benefrt512021 - £NIL). During the year ended 31 December 2022. expenses totalling £198 were reimbursed or paid directly to 2 Trustees {2021- £NIll in relation lo travel and conference Costs. 14. Intsngible assets Group and Charity Website Cost At 1 January 2022 20.988 A¢ 31 t)Kewthr 2022 20.988 Amortlsation At 1 January 2022 Charge for the year 12,156 6.996 At 31 December 2022 19.152 Net book value At 31 December 2022 1.836 Al 31 December 2021 8,832 P4e 34
NATIONAL ECZEMA SOCIETY IA Company Lirnited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OECEMBER 2022 15. Tangible fixed assets Group and Charfty Leasehold Improvemen Furni1? ts and fixtures Office equipment Computer eqvlpment Total Cost or valuation At 1 January 2022 41.470 2.493 3.873 24.189 72,025 At 31 December 2022 41,470 2h93 3073 24.189 72,025 Depclat10 Al 1 January 2022 Charge for the year 25.931 4.147 1.679 250 2,338 355 14.191 5,249 44.139 10,001 At 31 December 2022 30,078 1.929 2,693 19.440 54,140 Net book valu• At 31 December 2022 11.392 1.180 4.749 17,885 At 31 December 2021 15.539 814 1.535 9.998 27,886 Page 35
NATIONAL ECZEMA SOCIETY IA Company Limltsd by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 16. Flxed asset Investments Inveslrnent in subsidiary Company Charlty Cost or valuation At 1 January 2022 100 At 31 December 2022 100 Page 36
NAmON ECZEIAA SOCIETY IACoMwryLvnW ty Guarhts•l NOTES TO The FINA1 STATEMEIITS FOR THE YEAR ENDED31 tJECEMBER2022 Primclp•l ubsldl•ri The Tolbiry ¥Ms a c4theetrArty. R•gkMervd prtnclp4 Holding Included In plxtrof IvJJin•s toTrwlld¢iDn 11 Lond. NW1 Yes N4m• N•t Ivdbilltle y•¥ Er2em8 Trnding Linrted 4109 {5.LV21 18931 {29N251 The resulls of Eaema TrThng Lttnrfed ue in E¢ Try nol meetthty audit thtPshohJ IheTefore I require an alklrt for the endBd 31 2021 r5 to rrwnaywnth and rnin¥nal 3dvertiwng and rnitBd. Pèp 37
NATIONAL ECZEMA SOCIETY {A Company Limited by Guavants•l IIOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 17. Debtor5 Gioup 2022 Group 2021 Charity 2022 Charty 2021 Due within one year Trade debto Amounts owed by group underL*ings Other debtor5 Prepawnents and accrued inccwne 26.160 24,500 24,500 51,557 124,611 10,404 93.367 .219 13.066 26.219 13.066 124.611 10.404 65.445 159,515 132.652 211,072 18. Cieditors.. Amounts falling due withln one year Group 2022 Group 2021 Charlty 2022 Charty 2021 Trade credf(OTS Other taxation and KKial $8curity Other creditors A¢cruals and deferred in¢K 4.821 12,761 7.770 89.676 5.680 12.616 6.995 89.849 4,821 12,761 7,770 87,676 12,616 6.995 91.649 116.940 115.028 115.140 113,228 Group Group 2021 Charity 2022 Charty 2021 Deferred Income Deferred income at 1 January Resources deferred during the year Amounts released piev¥)us pertods 75.422 103.016 78.080 75,422 173.6221 {103,0161 73.622 78.080 173,622) 103,016 73,622 (103,016) Deferred Income at 31 December 79.880 75,422 78.080 73,622 Deferred in¢ome nSistS of membershp inm rekkn.ng lo firture peri¢xts. P4e 38
NATIONAL ECZEMA SOCIETY {A C¢>mpany Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OECEMBER 2022 19. Cr•ditors: Amounts falling due after more than on• year Group 2022 Group 2021 Charity 2022 Charty 2021 Pension Scheme deftit 4.264 8.774 4,264 8,774 Through its past partipati. the Group has a liabilty to a pension sd*me called the Series 3 Growth PLan, which closed in 2013. Since then. the Group has participated in a defined contribution pension scheme for employees. operated by workplace pension provthr TPT. The Chanty is p3rti¢ipating in a recovery pkn to eliminate ils Series 3 scheme defi¢it over a ten year period. The Pensions Trust. the s¢heme administrator. has however advised that the amount of employer debt on the aliemalive of vlrthdrawal from the Series 3 herne has been eslimaled by aduaries to have been £200,161 as at 31 December 2016. As the Charity intends lo continue participating in the recovery plan. no provision ha5 been made for this potential wrthdrawal debt however. the Society accounted for the present value of all remaining contribulK)n$ under the recovery plan in the 2017 accounts al their present value of £120.000. as thised by the heft administrator. This liability has been adjusted annualty to urmnd the relev1 discount applied. In order to meet their share of the shortfall. the Charity has been asked to pay additional contributions to the scheme until 2025. A full aduarial valuation was carried out by the actuaries at 30 September 2017 and the fundirtg shortfall calculated at that dale gave rise to a remeasurement reduction of £15.624 in the deficit as at 31 December 2018. The deficit of the scheme is £8.587 (2021- £158T9J al 31 December 2022. The payment by the Charty in the year was £7,105 (2027 - £15,333) wfth an Inte$1 payment of £130 f2021- £155) and a revaluation gain of £317 (2021- £(180J). In addth"on. the Charrty elected to switch, wilh effect from 1 October 2013, from Series 3 to Series 4. a defined contribution scheme. The pension cost in the accounts represents amounts payable by the charity as ordinary employef ¢ontribulion5 to the Series 4 defined ¢onlribulion ftjnd. During the year employer ntrib(K}nS of £8.470 (2021- 16.857). intet of £130 (2021- £155), aduarial Igains)/losses of £317 (2021- £(180)J and remeasuremenls for amendments to the contribution schedule of £Nil (2021- £(33.959)J have been charged lo the Consolidated Statement of Financial Activities, along wrth scheme costs of £3,625 (2021.. £Nil). There were no accrued contributions at 31 December 2022 (2027 - £NIL) but there is a liabilty of È8.587 (2021- £15,879) for future contributtons under the Series 3 Recovery Plan. Of this £4,323 (2021- £7. 105) ts reported in Credttors.. Amounts lalling due wlhin one year as part of Other creditors and £4.264 (2021- £8. 774) is reKk)rted in Creditors.. Amounts falling due after more then one ye¥. Page 39
NATIONAL ECZEMA SOCIETY IA Company Llmited by Guarnntee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDEO 31 DECEMBER 2022 20. Statement of funds Statement of funds- ¢urrent year Balance at 31 Gainsl 09¢gmber {Lossesl 2022 Balance at 1 January 2022 Transfers Inl{outl Income Expenditure Unrestricted funds Designated funds Fixed asset fund 36.718 115.8791 (16.997) 13.755) 19,721 {8,587} 110.000 Pension reserve Research lund 10.730 110.000 317 20.839 (20.752) 120.730 317 121.134 G•noral lunds General funds 699.114 337.808 (393.007) 1120.730) 523.185 Total Unrestri¢t funds 719.953 337.808 1413.759) 317 644,319 R•strict•d funds Research 1,738 5,013 6.751 Total of funds 721.691 342.821 1413.759) 317 651,070 Page 40
NATIONAL ECZEhlA SOCIETY IA Company Llmited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Statement of funds {continuèd) Statement oflunds - prlor y•ar Balance at 31 Gainsl December {Lossesl 2021 Balan al l January 2021 Transfets inlout Income ExperKlrture Unrestrl¢ted funds Designaled funds Fixed asset fund PensM)n reseNe 53,880 165.196) (19.3081 11551 2.146 15.333 36,718 {1 S.8791 34.139 111.316) {19.4631 17.479 34.139 20,839 Gener41 funds General funds 535.197 535,712 {354.3161 117.479) 699,114 Totsl Unrestricted funds 523.881 S35.712 (373.7T91 34.139 719.953 Restricted lund$ Research 12.488 (10.750) 1,738 Total of lund5 536.369 S35.712 (384.5291 34.139 721,691 Page 41
NATIONAL ECZEMA SOCIETY IA Company Llmited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Statement of lunds (continued) nated lunds The Pension reserve has been esla)lished lo sh# the pension deficil payments in regards to defined benefit pension scheme. This pension scheme is being treated as a defined contribution pension scheme as a reliable estimate cannot be made of the liabilty at the year end. The transfer of £10,730 was made to separate the deficrt payments due as at 31 Decembef 2022 from the Unre5tricled general fund. Actuarial gains l {k)sses) are charged lo thks fund as they arise. The Fixed asset fund has been established lo rellecl the fun¢Js tied up in Tangible and Intangible fixed assets and agrees back to the Net Book Value presented the Consolidated Balance Sheet. Depie¢iabon is charged to this fund as expenditu. The Research fund has been established lo designate funds lor research into the causes and treatment of eczema, which is a key airn of the Siety. The Society will provide grants to SearCherS on a periodic basis and it is necessary to designate sfftient re5eNes to fund the expected 9ranl costs. The fund is expected to be utilised and grants awarded ccThmenong in the finanual year to 31 December 2024. Unrestricted fvnds General funds reffle¢ts fvnds whith are avaiLable for use at the dIretIon of the Trustees in furtherance of the general objectNes of the Chanty and which have not been designated for other putP05es. The Research fund exists lo proyide resources for research into the causes of eczema, with the aim of developing more effective treatments or a cure. Page 42
NATIONAL ECZEMA SOCIETY IA Company Limited by Guarnnleel NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENOEO 31 DECEMBER 2022 21. Analysis of net assets between funds Analysis of net assets between funds- current year Unrestricted Restrlcted funds funds 2022 2022 Total funds 2022 Tangible fixed assets Intangible fixed assets Current assets cdorS due within one year Credrtors due more than one year 17.885 1.836 745.802 (114.456) (6,748) 17.885 1.836 752.553 1114.4561 16.7481 6.751 Total 644.319 6,751 6S1.070 Analysls of net assets beivRen funds- prior year Unrestricled funds 2021 Reslricled funds 2021 Total fvnd5 2021 Tangible fixed assets Intsngible fixed assets Current assets Creditors due wlhin one year Creditors due in mre than one year 27,886 8,832 807,037 (115,0281 18,7741 27,886 8,832 808.775 {115,0281 18,7741 1.738 Total 719,953 1,738 721.691 Page 43
NATIONAL ECZEMA SOCIEr¢ IA Company Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENOED 31 DECEMBER 2022 Reconciliation of net movement in funds tts net cash flow fvom operating activities Group 2022 Group 2021 Net incomelexpenditure for the year (as per Statement of Financk41 Activities) 170.938 151.183 Adjustments for: Depreciation charges Amortisalion charges Investment income Decreasel{increase) in debtors IDe¢reaSeifin8$e in creditors Actuarial Gans l (ioss) penston 15 10,001 6,996 11,4321 94.070 12,S981 317 12.312 6,996 {8561 {114.754) {2,086) 14 17 18 Net ¢ash provid•d by op•rating activities 36.416 52.795 23. Analysls of cash and cash equivalents Group 2022 Group 2021 Cash n hand 687,108 649,260 Total cash and cash equivalents 687,108 649.260 Anaty$i$ of Changes in net d•bl At31 D•¢emb•r 2022 January 2022 Cash flows Co8h at bank and in hand 649.260 37.848 687,108 649.260 37.848 687,108 Pa3e 44
NATIONAL ECZEMA SOCIETY IA Company Llmltgd by Guaranteel NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 25. Operating lthis• c<>mmitments At 31 D8¢emb8r 2022 the Group and the Clty had commitsnents to make future minimum lease payments under non-cancellatrAe cyernting Se$ a$ folows.. Group 2022 Group 2021 Charity 2022 Charity 2021 Not later than 1 year Later than 1 not later than 5 yea 21.000 25.333 21.000 46.333 21.000 25.333 21.000 46,333 46.333 67,333 46.333 67.333 The following lease PaentS have b8en rectrani5ed as w expense in the Statement of Financial AdNilie$.' Group 2022 Group 2021 Charity 2022 Charity 2021 Operating lease rentals 21.000 20.833 21.000 20,833 26. Related party transactions In the year ended 31 Dmber 2022. un$trd don*w)ns of £1,158 (2021- £1.200} were made by the Trustees of the Charity. Page 45